A prospective, open label, non-comparative, observational, 24 weeks multi centre study of TriohaleÂ®(Ciclesonide/Formoterol/Tiotropium FDC) administered through pressurized meter dose inhaler(pMDI) with or without spacer or dry powder inhaler in patients with COPD.

Cipla Ltd0 个研究点目标入组 300 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patient is ready to sign informed consent form
•2. Patients of either sex above 40 years of age with a confirmed diagnosis of COPD (GOLD updated January 2014)
•3. Patient able to use the Revolizer or Rotahaler dry powder inhaler, pMDI or pMDI with spacer and perform the Spirometry.
•4. TriohaleÂ®/triple therapy naÃ¯ve patients who are assessed to benefit from the intake of TriohaleÂ® (Investigator adjudicated need to step-up to triple therapy due to increased symptoms or clinical deterioration or frequent exacerbation).

•1. Patient Known or suspected hypersensitivity to combination or any other constituents of the Investigational Medicinal Product (IMP) & study drugs.
•2. Actively participating in any clinical trial or participated in past 1 month

发起方